|
T16369 |
O-Desmethyl gefitinib
|
|
EGFR
|
|
O-Desmethyl gefitinib inhibits EGFR (IC50: 36 nM in subcellular assays). In human plasma, O-Desmethyl gefitinib is an active metabolite of Gefitinib. The formation of O-desmethyl gefitinib is dependent on the CYP2D6 acti... |
|
T5437 |
Gefitinib-based PROTAC 3
|
|
EGFR
,
PROTACs
|
|
Gefitinib-based PROTAC 3, conjugating an EGFR binding element to a VHL ligand via a linker, induces EGFR degradation with DC50s of 11.7 nM and 22.3 nM in HCC827(exon 19 del) and H3255 (L858R mutantion) cells, respectivel... |
|
T11384 |
Gefitinib-d8
|
ZD1839 D8,Gefitinib D8 |
Others
|
|
Gefitinib is an EGFR tyrosine kinase inhibitor, with IC50 of 2-37 nM in NR6wtEGFR cells. Gefitinib D8 is a deuterium labeled Gefitinib. |
|
T65550 |
Gefitinib analog III
|
4-((3-Chloro-4-fluorophenyl)amino)-7-methoxyquinazolin-6-yl acetate |
Others
|
|
Gefitinib analog III (4-((3-Chloro-4-fluorophenyl)amino)-7-methoxyquinazolin-6-yl acetate) has potential anti-inflammatory and anti-tumor activity and can be used to study its interactions and activity in organisms. |
|
T40785 |
Gefitinib impurity 1
|
|
|
|
Gefitinib impurity 1 is a compound derived from Gefitinib, a potent and selective EGFR tyrosine kinase inhibitor (IC 50 = 33 nM). This orally active compound selectively inhibits tumor cell growth stimulated by EGF (IC 5... |
|
T15268 |
FAAH-IN-2
|
O-Desmorpholinopropyl Gefitinib |
FAAH
,
Autophagy
|
|
FAAH-IN-2 (O-Desmorpholinopropyl Gefitinib) is a potent inhibitor of FAAH(fatty acid amide hydrolase). |
|
T1181L |
Gefitinib hydrochloride
|
|
|
|
Gefitinib hydrochloride (ZD1839 hydrochloride) is a potent and orally active EGFR tyrosine kinase inhibitor (EGFR-TKI) (IC 50 = 33 nM) that selectively inhibits EGF-stimulated tumor cell growth (IC 50 = 54 nM) and that b... |
|
T19489 |
O-Desmethyl gefitinib D8
|
|
EGFR
|
|
O-Desmethyl gefitinib D8 is a deuterium labeled O-Desmethyl gefitinib that is an active metabolite of Gefitinib in human plasma. |
|
T11385 |
Gefitinib N-oxide
|
|
Others
|
|
Gefitinib is an EGFR tyrosine kinase inhibitor, with IC50 of 2-37 nM in NR6wtEGFR cells. Gefitinib N-oxide is the N-oxide derivative of Gefitinib. |
|
T18316 |
MC-Sq-Cit-PAB-Gefitinib
|
|
Others
|
|
MC-Sq-Cit-PAB-Gefitinib is a potent antitumor drug-linker conjugate for Antibody-Drug Conjugates (ADC), utilizing Gefitinib—an EGFR tyrosine kinase inhibitor—connected through the MC-Sq-Cit-PAB ADC linker. |
|
T63630 |
Gefitinib dihydrochloride
|
|
|
|
Gefitinib dihydrochloride is a potent, selective, orally active EGFR tyrosine kinase inhibitor (IC50: 33 nM). Gefitinib dihydrochloride selectively inhibits EGF-stimulated tumor cell growth with an IC50 value of 54 nM an... |
|
T65585 |
Gefitinib impurity 5
|
|
|
|
Gefitinib impurity 5 is a useful organic compound for research related to life sciences. The catalog number is T65585 and the CAS number is 199327-61-2. |
|
T67092 |
Gefitinib impurity 2
|
|
|
|
Gefitinib impurity 2 is a useful organic compound for research related to life sciences and the catalog number is T67092. |
|
TMIH-0402 |
O-Desmethyl Gefitinib-d8
|
|
|
|
O-Desmethyl Gefitinib-d8 is a deuterated compound of O-Desmethyl Gefitinib. O-Desmethyl Gefitinib has a CAS number of 847949-49-9. O-Desmethyl gefitinib inhibits EGFR (IC50: 36 nM in subcellular assays). In human plasma,... |
|
T73627 |
Gefitinib N-oxide hydrochloride
|
|
|
|
Gefitinib N-oxide hydrochloride, an N-oxide derivative of Gefitinib, acts as an EGFR tyrosine kinase inhibitor. Demonstrating an IC50 range of 2-37 nM in NR6wtEGFR cells, it emphasizes its efficacy in inhibiting the enzy... |
|
T77875 |
Mc-Val-Cit-PAB-Gefitinib chloride
|
|
|
|
Mc-Val-Cit-PAB-Gefitinib chloride is a conjugate agent-linker for antibody-drug conjugates (ADCs) that combines Gefitinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, with the proprietary ADC li... |
|
T81714 |
N3-PEG8-Phe-Lys-PABC-Gefitinib
|
|
|
|
N3-PEG8-Phe-Lys-PABC-Gefitinib is an antibody-drug conjugate (ADC) agent-linker complex exhibiting potent antitumor activity. It incorporates the orally active EGFR tyrosine kinase inhibitor Gefitinib, tethered by the cl... |
|
T6092 |
Sapitinib
|
AZD-8931 |
EGFR
|
|
Sapitinib (AZD-8931) , a reversible, ATP competitive inhibitor of EGFR(IC50=4 nM), ErbB2(IC50=3 nM) and ErbB3(IC50=4 nM), is more effective over Gefitinib or Lapatinib against NSCLC cell, 100-fold more specific for the E... |
|
T35147 |
WZ4002-hydroxy
|
WZ4002 analog, WZ4002 demethyl derivate,WZ 4002-hydroxy,WZ-4002-hydroxy |
|
|
WZ4002-hydroxyl is a WZ4002 derivative or WZ4002 analogue in which methoxy is replaced by hydroxyl and can be detected in 50% of patients with clinical resistance to gefitinib or erlotinib. WZ4002 has a basic chemical sk... |
|
T71436 |
D561-0775
|
|
|
|
D561-0775 is a direct AMPK agonist, showing potential anti-cancer activity via inducing apoptosis, cell cycle arrest, suppressing glycolysis and cholesterol synthesis after activation of AMPK in gefitinib-resistant H1975... |
|
T74457 |
EGFR-IN-42
|
|
|
|
EGFR-IN-42 (Compound 17b), a potent EGFR inhibitor, demonstrates single-digit nanomolar activity by covalently linking tamoxifen or endoxifen with gefitinib, retaining both ER antagonist activity and EGFR inhibition, res... |
|
T41155 |
MS 154
|
|
|
|
MS 154 is a potent and selective cereblon-recruiting Degrader (PROTAC®) of mutant epidermal growth factor receptor (EGFR), comprising a cereblon-binding moiety joined by a linker to gefitinib(Iressa). MS 154 decreases EG... |
|
T11157 |
EGFR-IN-1
|
|
EGFR
|
|
EGFR-IN-1, an orally active and irreversible selective inhibitor targeting L858R/T790M mutant EGFR, exhibits strong antiproliferative and antitumor activity, particularly against H1975 cells and first line mutant HCC827 ... |
|
T78841 |
Nrf2-IN-3
|
|
|
|
Nrf2-IN-3 (Compound R16), a Nrf2 inhibitor, binds to KEAP1 mutants (G333C mKEAP1) thereby restoring the impaired KEAP1/NRF2 interactions. This restoration sensitizes KEAP1-mutant cancer cells to chemotherapeutic agents, ... |
|
T75261 |
EGFR-IN-1 TFA
|
|
|
|
EGFR-IN-1 TFA is an orally active and irreversible L858R/T790M mutant selective EGFR inhibitor. EGFR-IN-1 TFA potently inhibits Gefitinib-resistant EGFR L858R, T790M with 100-fold selectivity over wild-type EGFR . EGFR-I... |
|
T69403 |
AZD-3409
|
|
|
|
AZD-3409 is a potent prenyl transferase inhibitor. AZD-3409 showed higher potency than lonafarnib. The mean IC(50) for cytotoxicity of AZD3409 was 510 in MEF cells, 10,600 in A549 cells and 6,170 in MCF7 cells, respectiv... |
|
T74458 |
EGFR-IN-43
|
|
|
|
EGFR-IN-43 (Compound 17c) is a highly effective EGFR inhibitor, exhibiting activity in the single-digit nanomolar range. It uniquely combines tamoxifen or endoxifen with the EGFR inhibitor gefitinib through a covalent bo... |
|
T83890 |
Flavokawain 1i
|
Flavokavain 1i |
|
|
Flavokawain 1i, a derivative of chalcones flavokawain A, flavokawain B, and flavokawain C, exhibits anticancer and antiviral properties. At a concentration of 30 µM, it suppresses the growth of gefitinib-resistant H1975 ... |
|
T41156 |
MS 39
|
|
|
|
MS 39 is a highly effective, highly affinity and selective depressant of mutant epidermal growth factor receptor (EGFR) with high efficiency, high affinity and selectivity. MS 39, conjured by gefitinib to VHL ligand via ... |
